Center-Authored Papers

Filters: Keyword is Models, Economic  [Clear All Filters]
C
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Cosler LE, Calhoun EA, Agboola O, Lyman GH.  2004.  Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.. Pharmacotherapy. 24(4):488-94. Abstract
Cosler LE, Lyman GH.  2009.  Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.. Cancer investigation. 27(10):953-9.
D
Dierick-van Daele ATM, Steuten LM, Romeijn A, Derckx EWCC, Vrijhoef HJM.  2011.  Is it economically viable to employ the nurse practitioner in general practice? Journal of clinical nursing. 20(3-4):518-29. Abstract
E
Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH.  2008.  Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 11(2):172-9. Abstract
H
Hummel MJ, Boomkamp ISM, Steuten LM, Verkerke BGJ, IJzerman MJ.  2012.  Predicting the health economic performance of new non-fusion surgery in adolescent idiopathic scoliosis.. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 30(9):1453-8. Abstract
L
Lyman GH.  2000.  A predictive model for neutropenia associated with cancer chemotherapy.. Pharmacotherapy. 20(7 Pt 2):104S-111S. Abstract
Lyman GH.  2003.  Balancing the benefits and costs of colony-stimulating factors: a current perspective.. Seminars in oncology. 30(4 Suppl 13):10-7. Abstract
O
Othus M, Bansal A, Koepl L, Wagner S, Ramsey S.  2017.  Accounting for Cured Patients in Cost-Effectiveness Analysis.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20(4):705-709. Abstract
R
Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ.  2008.  An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.. PharmacoEconomics. 26(4):329-39. Abstract
Retèl VP, van der Molen L, Hilgers FJM, Rasch CRN, L'Ortye AAAMHJ, Steuten LM, van Harten WH.  2011.  A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.. BMC cancer. 11:475. Abstract
S
Sander B, Nizam A, Garrison LP, Postma MJ, Halloran ME, Longini IM.  2009.  Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 12(2):226-33. Abstract
Steuten LMG, Vrijhoef HJM, Landewé-Cleuren S, Schaper N, Van Merode GG, Spreeuwenberg C.  2007.  A disease management programme for patients with diabetes mellitus is associated with improved quality of care within existing budgets.. Diabetic medicine : a journal of the British Diabetic Association. 24(10):1112-20. Abstract
Steuten LMG, Lemmens KMM, Nieboer AP, Vrijhoef HJM.  2009.  Identifying potentially cost effective chronic care programs for people with COPD.. International journal of chronic obstructive pulmonary disease. 4:87-100. Abstract
V
Vallejo-Torres L, Steuten L, Parkinson B, Girling AJ, Buxton MJ.  2011.  Integrating health economics into the product development cycle: a case study of absorbable pins for treating hallux valgus.. Medical decision making : an international journal of the Society for Medical Decision Making. 31(4):596-610. Abstract